Earnings Call Transcripts

Access detailed transcripts and key takeaways from company earnings calls

All Earnings Calls

WTRG November 5, 2025

Essential Utilities Q3 2025 Earnings Call - Merger with American Water Sets Stage for Transformative Growth

Essential Utilities reported a solid third quarter with GAAP EPS up 32% year-over-year to $0.33, driven by rate increases and operational execution in both water and natural gas segments. The standout...

  • Essential Utilities announced a merger with American Water, creating the largest U.S. water and wastewater utility with a combined rate base of ~$34 billion and serving 5 million connections across 17 states.
  • The merger is expected to generate synergy and create a stronger, low-beta investment opportunity with targeted 7-9% EPS and dividend growth anchored in multi-decade infrastructure needs.
  • Q3 GAAP EPS rose 32% year-over-year to $0.33, driven primarily by rate increases and reduced income tax expense.
  • +9 more takeaways
SKT November 5, 2025

Tanger Outlets Q3 2025 Earnings Call - Strong Leasing Momentum and Strategic Growth Elevate Full-Year Guidance

Tanger Outlets delivered a robust third quarter fueled by an 11% year-over-year increase in core FFO per share and 4% same-center NOI growth. The company's record leasing activity, highlighted by over...

  • Core FFO per share rose 11% to $0.60, driven by 4% same-center NOI growth and strategic external growth.
  • Record leasing volume included 600+ transactions totaling 2.9 million sq ft, boosting occupancy to 97.4%.
  • Portfolio sales productivity hit an all-time high at $475 per square foot.
  • +7 more takeaways
ZBH November 5, 2025

Zimmer Biomet Q3 2025 Earnings Call - Innovation Cycle Drives US Growth Amid Emerging Market Challenges

Zimmer Biomet reported a 5% organic constant currency revenue growth in Q3 2025, with a notable acceleration in the US business to 5.6%, marking the best growth since mid-2023. The company highlighted...

  • Zimmer Biomet achieved 5% organic constant currency revenue growth in Q3 2025, led by 5.6% growth in the US market—the strongest US performance since mid-2023.
  • Late-quarter disruptions including distributor order cancellations in Eastern Europe, Middle East, and Latin America, as well as softness in restorative therapies, negatively impacted growth by nearly 120 basis points.
  • Strong product adoption in US knees with Persona Osteotide cementless knee representing nearly 30% of US total knee implants, targeting over 50% penetration by end of 2027.
  • +10 more takeaways
ESTA November 5, 2025

Establishment Labs Q3 2025 Earnings Call - First Positive EBITDA Quarter Fueled by U.S. Market Momentum

Establishment Labs reported a strong Q3 2025 with a 34% revenue jump to $53.8 million, driven primarily by a booming U.S. business that surged 16% sequentially despite a traditionally slow quarter. Th...

  • Establishment Labs grew global revenue by 34% in Q3 2025 to $53.8 million, including $11.9 million in the U.S.
  • The company achieved its first positive adjusted EBITDA quarter at $1.2 million, beating prior expectations.
  • Gross profit margin exceeded 70% (70.1%) for the first time, driven by higher margin sales in the U.S.
  • +13 more takeaways
DDD November 5, 2025

3D Systems Q3 2025 Earnings Call - Strategic Pivot Amid Revenue Decline Driven by Tariff-Induced Capex Uncertainty

3D Systems reported a challenging Q3 2025 with revenue declining 13.8% year-over-year to $91.2 million, reflecting muted capital expenditures across 3D printing OEMs amid tariff uncertainties. The com...

  • Q3 2025 revenue declined 13.8% year-over-year to $91.2 million, driven by continued soft capital expenditures from customers due to tariff uncertainties.
  • Company closed sales of non-core software assets Octane and 3Dexter to focus on proprietary technologies, with a modest financial impact expected in Q4.
  • Aggressive cost reduction initiatives underway targeting over $50 million in annualized savings by year-end, including organizational optimization and facility consolidations extending into early 2026.
  • +10 more takeaways
OI November 5, 2025

O-I Glass Q3 2025 Earnings Call - Profit Margins Surge Amid Volume Declines and Strategic Transformation

O-I Glass reported a robust third quarter with adjusted earnings per share of $0.48, surpassing both prior year figures and company estimates. While net sales remained stable at $1.7 billion, shipment...

  • O-I Glass achieved adjusted EPS of $0.48 in Q3 2025, exceeding prior year and internal forecasts.
  • Net sales held steady at $1.7 billion despite a 5% decline in shipment volumes, reflecting mixed consumer demand trends.
  • Volumes decreased due to weak beer and wine categories, partially offset by growth in non-alcoholic beverages, food, and RTDs.
  • +17 more takeaways
GDRX November 5, 2025

GoodRx Q3 2025 Earnings Call - Strategic Expansion of Manufacturer Solutions and Pharmacy Counter Integration

GoodRx delivered a solid Q3 2025 highlighted by a 54% year-over-year revenue growth in its manufacturer solutions segment, bolstered by new partnerships with Novo Nordisk and Amgen to provide direct-t...

  • GoodRx achieved 54% year-over-year revenue growth in manufacturer solutions, driven by expanded brand partnerships and new deals.
  • The company closed deals with Novo Nordisk and Amgen to offer significant cash price discounts on Ozempic, Wegovy, and Repatha, enhancing direct-to-consumer access.
  • Prescription transaction revenue declined 9% due to the completed Rite Aid pharmacy closures and reduced volume with an integrated savings PBM partner.
  • +13 more takeaways
LIVN November 5, 2025

LivaNova Q3 2025 Earnings Call - Strong Organic Growth and Strategic Investments Drive Margin Expansion

LivaNova reported a robust third quarter in 2025, delivering 13% organic revenue growth led by cardiopulmonary momentum and epilepsy segment advances across all regions. The company raised its full-ye...

  • LivaNova achieved 13% organic revenue growth in Q3 2025, driven primarily by cardiopulmonary and epilepsy segments.
  • Cardiopulmonary revenue increased 16% to $203 million, bolstered by over 20% growth in heart-lung machine (HLM) sales.
  • ESSENCE heart-lung machine placements accelerated in developed markets with a commercial launch in China begun in August, expected to materially contribute in 2026.
  • +13 more takeaways
SHOO November 5, 2025

Steve Madden Ltd Q3 2025 Earnings Call - Tariff Challenges Temper Growth Despite Strong Brand Momentum

Steve Madden’s third quarter 2025 results reveal a business navigating intense tariff-induced disruptions with a mix of resilience and strategic pivoting. New tariffs on Chinese imports caused wholesa...

  • Q3 revenue increased 6.9% to $667.9 million, but fell 14.8% excluding Kurt Geiger acquisition.
  • Wholesale revenue declined 10.7%, driven by a 19% drop excluding Kurt Geiger; tariff-related order cuts and shipment delays were key factors.
  • Direct-to-consumer (DTC) revenue surged 76.6%, or 1.5% excluding Kurt Geiger, reflecting strong digital engagement.
  • +13 more takeaways
BRLT November 5, 2025

Brilliant Earth Q3 2025 Earnings Call - Engagement Rings Rebound and Fine Jewelry Surges Amid Industry Headwinds

Brilliant Earth marked its 20th anniversary with strong third-quarter results, reporting a 10% year-over-year net sales increase that beat expectations. The company saw a key inflection point with eng...

  • Brilliant Earth achieved 10.4% year-over-year net sales growth in Q3 2025, surpassing guidance.
  • Engagement ring bookings, previously soft after a market normalization, returned to year-over-year growth signaling a bridal recovery.
  • Wedding and anniversary band bookings reached their highest ever, with strong growth in men's and women's collections.
  • +12 more takeaways